• Type:
  • Category:

Carl Zeiss Meditec AG Financial Results Q1 2021 / 22 | A Comprehensive Overview with CEO and CFO

Share

Excerpt

In this in-depth video presentation, Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditec AG, discuss the company’s financial performance during Q1-2021/22.

 

They provide an overview of the quarter’s results, including insights into the financials, new product releases, and the outlook for the future. As an MDAX- and TecDAX-listed company, Carl Zeiss Meditec AG is a leader in medical technology, specializing in ophthalmology and microsurgery solutions. With a global presence and a solid commitment to research and development, the company strives to continuously improve treatment results through innovative new products and increased efficiency.

 

Watch this comprehensive presentation to learn more about the company’s performance, products, and strategies.

Company Profile

The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. 

 

With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network.

 

Two Pillars of Business & Markets:

The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery

In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. 

In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments.

 

Markets:

The Carl Zeiss Meditec Group has operations all over the world. 

With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world’s most important markets.

 

Milestones & Innovations:

Research and development plays an important role within the Carl Zeiss Meditec Group. 

Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products

Carl Zeiss Meditec AG

Goeschwitzer Strasse 51-52

Jena 07745, Germany

phone +49 3641 220 116

Chapters

  • Introduction
  • Q1-2021/22: Overview
  • Q1-2021/22: Financials
  • New Products
  • Q1-2021/22: Outlook

Resources

Host

Dr. Markus Weber
CEO | Carl Zeiss Meditec AG

Justus Felix Wehmer
CFO | Carl Zeiss Meditec AG

Sebastian Frericks
Head IR | Carl Zeiss Meditec AG

Share

T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Elevator Pitches

More Company Presentations

Reviews for Carl Zeiss Meditec AG Financial Results Q1 2021 / 22 | A Comprehensive Overview with CEO and CFO

There are currently no reviews for Carl Zeiss Meditec AG Financial Results Q1 2021 / 22 | A Comprehensive Overview with CEO and CFO
Scroll to top